Hennion & Walsh Asset Management Inc. Boosts Stake in United Therapeutics Co. (NASDAQ:UTHR)

Hennion & Walsh Asset Management Inc. increased its stake in United Therapeutics Co. (NASDAQ:UTHR) by 31.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,286 shares of the biotechnology company’s stock after acquiring an additional 1,023 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in United Therapeutics were worth $1,536,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its holdings in shares of United Therapeutics by 1.1% in the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock worth $692,748,000 after purchasing an additional 22,978 shares in the last quarter. LSV Asset Management lifted its position in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after buying an additional 436,851 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in United Therapeutics by 4.0% in the second quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after buying an additional 22,683 shares in the last quarter. Pacer Advisors Inc. grew its position in United Therapeutics by 19.6% during the second quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after acquiring an additional 92,240 shares during the last quarter. Finally, Swedbank AB purchased a new position in shares of United Therapeutics during the first quarter worth approximately $97,316,000. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 25,000 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $833,350.26. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the sale, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at $947,597.55. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $323.38, for a total value of $8,084,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $833,350.26. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 102,812 shares of company stock valued at $35,251,926. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Stock Down 0.4 %

Shares of United Therapeutics stock opened at $348.65 on Friday. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $377.03. The company has a market cap of $15.46 billion, a P/E ratio of 16.48, a PEG ratio of 1.35 and a beta of 0.57. The company’s fifty day simple moving average is $354.00 and its two-hundred day simple moving average is $312.79.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter in the prior year, the firm earned $5.24 EPS. United Therapeutics’s quarterly revenue was up 19.8% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Co. will post 24.72 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on UTHR. HC Wainwright reaffirmed a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a report on Thursday, August 1st. Oppenheimer lifted their price objective on United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a report on Wednesday, August 28th. Jefferies Financial Group increased their target price on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a report on Monday, September 23rd. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, TD Cowen increased their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $361.33.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.